OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 6
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 6
Showing 6 citing articles:
Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis
Vito Terlizzi, Cristina Fevola, Martina Cecchetti, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 1
Vito Terlizzi, Cristina Fevola, Martina Cecchetti, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 1
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Donatello Salvatore, Paola Iacotucci, Angela Pepe, et al.
(2025)
Closed Access
Donatello Salvatore, Paola Iacotucci, Angela Pepe, et al.
(2025)
Closed Access
Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years
Rebecca S. Pettit, Bharathi Ravikumar
Pediatric Pulmonology (2025) Vol. 60, Iss. 4
Closed Access
Rebecca S. Pettit, Bharathi Ravikumar
Pediatric Pulmonology (2025) Vol. 60, Iss. 4
Closed Access
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
Angela Pepe, Cristina Fevola, Daniela Dolce, et al.
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Angela Pepe, Cristina Fevola, Daniela Dolce, et al.
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells
Filippo Scialò, Gustavo Cernera, Lorenza Polise, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10360-10360
Open Access | Times Cited: 2
Filippo Scialò, Gustavo Cernera, Lorenza Polise, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10360-10360
Open Access | Times Cited: 2
